Source comparison
CJC-1295 Growth Hormone Release Research: Clinical Trial Comparison
Teichman et al., JCEM 2006 (Phase I) 30–90 mcg/kg single SC injection 2–10× baseline (dose-dependent) 1.5–3× baseline 7–11 days Dose-dependent GH elevation with preserved pulsatility; no tachyphylaxis observed Ionescu & Frohman, Growth Hormone & IGF Research 2
This comparison does not assign a generated winner or score.
- Teichman et al., JCEM 2006 (Phase I)
- 30–90 mcg/kg single SC injection
- 2–10× baseline (dose-dependent)
- 1.5–3× baseline
- 7–11 days
- Dose-dependent GH elevation with preserved pulsatility; no tachyphylaxis observed
- Ionescu & Frohman, Growth Hormone & IGF Research 2006
- 60 mcg/kg weekly × 4 weeks
- 3–7× baseline
- 2.2–2.8× baseline
- Sustained across 28-day protocol
- Repeated weekly dosing maintained elevated GH/IGF-1 without receptor downregulation
- Native GHRH bolus (comparative reference)
- 1 mcg/kg IV bolus
- 5–15× baseline (transient)
- Minimal (insufficient duration)
- 20–40 minutes
- Rapid clearance limits research applications requiring multi-day observation
- MK-677 (ibutamoren) comparator
- 25 mg oral daily
- 2–3× baseline (tonic elevation)
- 1.4–1.9× baseline
- 24 hours per dose
- Produces more continuous GH elevation; does not preserve physiological pulsatility
- Professional Assessment
- CJC-1295 enables multi-day pulsatile GH research protocols impossible with native GHRH. The extended half-life, preserved secretion architecture, and lack of tachyphylaxis across repeated dosing make it the preferred tool for studying receptor dynamics, IGF-1 kinetics, and downstream anabolic signalling in controlled research settings.